Received Apr 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | UNK | — |
first dose of the Shingles vaccine 5 years ago and got second in february; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. Previously administered products included varicella zoster vaccine (Patient received first dose 5 years ago). In FEB-2025, the patient received the 2nd dose of Shingles vaccine. In FEB-2025, an unknown time after receiving Shingles vaccine, the patient experienced drug dose administration interval too long (Verbatim: first dose of the Shingles vaccine 5 years ago and got second in february). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 20-APR-2025 This case was reported by a patient via interactive digital media. Patient had a first dose of the shingles vaccine about 5 years ago, and got second dose in February. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccinations schedule. This case is one of the multiple linked cases.; Sender's Comments: US-GSK-US2025AMR048644:same reporter different patient US-GSK-US2025AMR048648:same reporter different patient US-GSK-US2025AMR048653:same reporter different patient US-GSK-US2025AMR048658:same reporter different patient US-GSK-US2025AMR048644:same reporter different patient US-GSK-US2025AMR048648:same reporter different patient